Common prognostic tests include The 21-gene recurrence score assay (based on Oncotype Dx™) The Amsterdam 70-gene profile (MammaPrint®) The 50-gene risk of recurrence score (PAM50 assay) In the US, most women with breast cancer have ER+ / PR+ / HER - breast cancer with negative axillary nodes.